Optimising Radiation Therapy in Head and Neck Cancers Using Functional Image-Guided Radiotherapy and Novel Biomarkers

  • STATUS
    Recruiting
  • participants needed
    73
  • sponsor
    Royal Marsden NHS Foundation Trust
Updated on 19 February 2024
cancer
metastasis
platinum-based chemotherapy
neutrophil count
squamous cell carcinoma of head and neck
squamous cell carcinoma
induction chemotherapy
chemoradiotherapy
carcinoma
head and neck cancer
neck cancer
oropharyngeal
head and neck carcinoma
advanced head and neck carcinoma
chemo-radiotherapy

Summary

This is a non-randomised study to develop personalised treatment approaches in participants with Locally Advanced Head and Neck Cancer (HNC) of the oropharynx and base of skull by integrating the use of MR-guided Adaptive Radiotherapy (MRgRT) and functional image-guided radiotherapy (FIgRT).

The study is made up of two parts:

  1. Feasibility planning study consisting of a total of 13 patients. This will include patients with either Human papilomavirus-associated (HPV-associated) oropharyngeal cancer (OPC), Human papilomavirus-negative (HPV-negative) OPC or Base of Skull HNC.
  2. Single centre prospective interventional phase I/II study (main study) made up of 3 independent arms (on the condition of success of the feasibility stage).
  3. Cohort 1: HPV-associated OPC consisting of 25 participants
  4. Cohort 2: HPV-negative OPC consisting of a minimum of 10 patients and a maximum of 53 participants
  5. Cohort 3: Base of Skull HNC consisting of 25 participants

Description

This study is looking at improving radiotherapy treatment for head and neck cancers by:

  1. Repeating the radiotherapy planning scan at weeks 2 and 4 of treatment so that investigators can adapt the radiotherapy to changes to the shape of the cancer and the patient's body. These changes can affect the accuracy and the radiotherapy doses delivered.
  2. Using a MR (magnetic resonance) scans to view and target the cancer with more precision.
  3. Identifying HPV negative oropharyngeal cancer who are non-responders and increasing the radiotherapy dose.

The 3 groups of patients are:

  1. Cancers of the oropharynx (middle of the throat) that test positive for HPV (human papilloma virus). If HPV is present, the cancer responds better to treatment and there is a higher chance of cure. In this group, the investigators aim is to reduce radiotherapy associated long-term side effects by sparing healthy tissue from high doses.
  2. If the oropharyngeal cancers test negative for HPV, they are less likely to respond well to treatment. The investigator's department has shown that investigators can predict which patients will respond to treatment using a special type of MR scan. Investigators will increase the dose of radiotherapy to HPV negative patients who are predicted to be non-responders with the aim of improving the chance of cure.
  3. Cancers that located at the base of the skull are not seen very well on CT scan. By using MR imaging, investigators can visualize the surrounding normal organs and the cancer better, target the cancer with more precision and adapt to changes to the healthy organs and tumour.

Investigators will also test if they can predict response to treatment by checking blood for fragments of the cancer and using a special MRI.

The study will be conducted at the Royal Marsden in Sutton only and will be followed up for 2 years.

Details
Condition head and neck cancer, head and neck cancer
Age 18-70 years
Treatment Adaptive Radiotherapy
Clinical Study IdentifierNCT04242459
SponsorRoyal Marsden NHS Foundation Trust
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Feasibility study and Main Study
Participants with stage III/IV ((American Joint Committee (AJC) Tumour, Nodes, Metastasis (TMN) on Cancer Version 7)) head and neck cancer planned for primary radical chemo-radiotherapy OR induction chemotherapy followed by chemoradiotherapy with concomitant platinum-based chemotherapy
Age between 18 and 70 years
Participant can provide informed consent
World Health Organisation (WHO) performance status 0 - 1
Creatinine Clearance >60ml/minute
Absolute Neutrophil Count >=1500/mcl
Platelets >=100,000/mcl
Haemoglobin >=9g/dl
Feasibility Study
Participants with either HPV associated OPC, HPV negative OPC or Base of Skull HNC
HPV associated OPC
Participants with histologically proven squamous cell carcinoma of the head and neck
p16 positive (defined as >70% cells staining positive)
<10 year pack smoking history
HPV negative OPC
Participants with histologically proven squamous cell carcinoma of the head and neck
p16 negative
>= 4cm in size
Base of skull Head and Neck Cancer
Participants with histologically proven squamous cell carcinoma or undifferentiated carcinoma of the head and neck

Exclusion Criteria

WHO performance status >=2
Participants with any previous malignancy except non-melanoma skin cancer
Participants with prior radiotherapy to the head and neck region
Participants with contraindications to MRI scan
Participants with contraindications to IV contrast agents
Participants with renal failure
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.